Gastroenterology and Hepatology - Global Oncology Academy

Episodes 1-16 of 37

Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
GI Insights
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
- Peter Buch, MD, FACG, AGAF, FACP
- Vivek Kaul, MD
Diagnosis and Management of Metastatic PDAC
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits
Chemotherapy Strategies for Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits
MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
0.25 credits 2 episodes
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 credits 2 episodes
Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
Clinician's Roundtable
Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
- Charles Turck, PharmD, BCPS, BCCCP
- Sara Enslin, PA
The Clinical Use of HER2-Targeted Therapies in Gastric Cancer: The Current and Emerging Landscape
The Clinical Use of HER2-Targeted Therapies in Gastric Cancer: The Current and Emerging Landscape
CME/CE
The Clinical Use of HER2-Targeted Therapies in Gastric Cancer: The Current and Emerging Landscape
0.50 credits
- Manish A. Shah, MD FASCO
0.50 credits
Enhancing HCC Outcomes Through Multidisciplinary Care
Enhancing HCC Outcomes Through Multidisciplinary Care
Project Oncology®
Enhancing HCC Outcomes Through Multidisciplinary Care
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah Lee, MD
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Project Oncology®
Optimizing HCC Screening: Strategies to Overcome Common Barriers
- Hannah Lee, MD
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
Project Oncology®
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
- Jody Takemoto, PhD
- Robert Wong, MD
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
Project Oncology®
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
- Jody Takemoto, PhD
- Robert Wong, MD
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
Project Oncology®
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
- Jody Takemoto, PhD
- Robert Wong, MD
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
MinuteCE®
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
1.25 credits 11 episodes
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 credits 11 episodes
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits

Prev
1
2
3
Next

1/3